🇺🇸 FDA
Pipeline program

GC4419

GTI-4419-101

Phase 2 small_molecule completed

Quick answer

GC4419 for Pancreatic Cancer is a Phase 2 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Galera Therapeutics
Indication
Pancreatic Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials